Last reviewed · How we verify
artesunate-atovaquone-proguanil
Artesunate-atovaquone-proguanil, developed by the Armed Forces Research Institute of Medical Sciences in Thailand, is a marketed antimalarial drug with a key composition patent expiring in 2028. The drug's primary strength lies in its combination therapy approach, which may offer enhanced efficacy and reduced resistance compared to monotherapies. The primary risk is the potential for increased competition as the key patent expires in 2028.
At a glance
| Generic name | artesunate-atovaquone-proguanil |
|---|---|
| Sponsor | Armed Forces Research Institute of Medical Sciences, Thailand |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) (PHASE1)
- The ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in Cambodia (PHASE4)
- Drug Combinations of Atovaquone-Proguanil (AP) With ACT (PHASE4)
- Safety and Efficacy Study of IV Artesunate to Treat Malaria (PHASE2)
- Chloroquine Alone or in Combination for Malaria in Children in Malawi (PHASE3)
- Safety of Artemether - Lumefantrine, and Other Malaria Drugs and Their Effect on the Auditory Function (PHASE4)
- Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: